黄芪多糖防治蒽环类药物心脏毒性的临床观察

Abstract
Figure/Table
References (21)
Related Citation (15)

Download: PDF (354 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To discuss the clinical effect of astragalus polysaccharide in preventing the cardiotoxicity of anthracyclines. Methods Eighty patients diagnosed as breast cancer or malignant lymphoma in Cancer Center of Guangzhou Medical University from September 2013 to March 2016 were selected and randomly divided into prevention group and conventional group according to random number table method, with 40 cases in each group. The conventional group was given regular anthracyclines drugs [breast cancer: Cyclophosphamide (CTX) + Epirubicin (EPI) / Theprubicin (THP) + Fluorouracil (5-FU), malignant lymphoma: CTX+EPI/THP, Vindesine (VDS)+Prednisone] and 1.0 g sodium phosphocreatine+100 mL normal saline, intravenous drip, on basis of which, the prevention group was added with 250 mg astragalus polysaccharides+500 mL normal saline, intravenous drip. The levels of plasma B-type brain natriuretic peptide (BNP), nitric oxide (NO), platelet alpha granule membrane protein (GMP-140) were detected by enzyme-linked immunosorbent assay (ELISA). The left ventricular ejection fraction (LVEF) was detected by ECG. The quality of life was assessed by Kamofsky performance status (KPS), followed up for 6 months. Results The effective rate between prevention group and conventional group had no statistically significant difference (P ＞ 0.05). The levels of plasma BNP, GMP-140 in prevention group were significantly lower than those of conventional group, the levels of plasma NO and LVEF were higher than those of conventional group, the differences were statistically significant (P ＜ 0.05). The KPS scores of prevention group after treatment for 3, 6 months were significantly higher than those of conventional group, the differences were statistically significant (P ＜ 0.05). Conclusion Astragalus polysaccharides can effectively reduce the cardiac toxicity induced by anthracycline, which is helpful to improve the quality of life, and it has no side effects on the curative effect.

Key words： Astragalus polysaccharide Anthracyclines Cardiotoxicity Quality of life Curative effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	KONG Jiaxin1 SU Xuchun1 DAI Shilei1 DENG Yuemin2 CHENG Ling1 SONG Jing1

Cite this article:

KONG Jiaxin1 SU Xuchun1 DAI Shilei1 DENG Yuemin2 CHENG Ling1 SONG Jing1. Clinical observation of astragalus polysaccharide in preventing the cardiotoxicity of anthracyclines[J]. 中国医药导报, 2017, 14(20): 136-139.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2017/V14/I20/136

[1] 刘良，刘兆喆，刘永叶，等.小剂量卡维地洛联合坎地沙坦在乳腺癌辅助化疗中预防蒽环类药物心脏毒性的作用[J].中华肿瘤杂志，2013，35（12）：936-940.
[2] 姚铁柱，徐志宏，马景涛，等.心脉隆注射液对曲妥珠单抗和蒽环类药物序贯化疗乳腺癌患者致心脏毒性气虚血瘀证的保护作用[J].中国实验方剂学杂志，2016，22（6）：154-158.
[3] 欧幸甘.黄芪多糖预防及治疗宫颈癌化疗所致骨髓抑制的疗效观察[J].吉林医学，2012，33（13）：2774-2775.
[4] Armstrong GT，Oeffinger KC，Chen Y，et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer [J]. J Clin Oncol，2013，31（29）：3673-3680.
[5] 中华医学会核医学分会PET与分子影像学组.淋巴瘤18F-FDG PET/CT显像临床应用指南（2016版）[J].中华核医学与分子影像杂志，2016，36（5）：458-460.
[6] 李惠平.进展期乳腺癌诊疗优化和ABC1指南部分解读[J].癌症进展，2013，11（6）：506-509.
[7] 张绪良，周俊伟，毛哲玉，等.金龙胶囊联合TEC方案在乳腺癌新辅助化疗中的疗效及安全性观察[J].中国医学前沿杂志：电子版，2016，8（4）：42-44.
[8] 叶久红，李祖同，王霞，等.晚期癌症病人生活质量自评量表的编制及试测[J].护理研究：上旬版，2009，23（6）：1497-1499.
[9] 杨芳，贺建昌，杨润祥，等.蒽环类药物心脏毒性的预防与减轻[J].中国医刊，2014，49（2）：14-16.
[10] 周君，姚昶，卞卫和，等.三黄抗氧化方改善乳腺癌术后蒽环类药物化疗心脏毒性临床观察[J].辽宁中医药大学学报，2016，18（7）：154-157.
[11] Emerenziani GP，Gallotta MC，Meucci M，et al. Effects of aerobic exercise based upon heart rate at aerobic thresh-old in obese elderly subjects with type 2 diabetes [J]. Int J Endocrinol，2015，20（15）：695-697.
[12] 熊辉霞.右丙亚胺对老年恶性淋巴瘤患者蒽环类药物化疗中的心脏保护作用[J].中国现代药物应用，2015，9（15）：123-124.
[13] Silverman LB. Balancing cure and long-term risks in acute lymphoblastic leukemia [J]. Hematology Am Soc Hematol Educ Program，2014，2014（1）：190-197.
[14] 王培，张晟，张霄蓓，等.右丙亚胺对接受含蒽环类药物化疗乳腺癌患者的心脏保护作用[J].中华肿瘤杂志，2013， 35（2）：135-139.
[15] 赵晓宁，弥海宁，李兴文，等.黄芪多糖联合化疗对54例中晚期胃癌的临床疗效分析[J].中国中医基础医学杂志，2012，18（9）：994.
[16] 许敬.注射用黄芪多糖联合甲地孕酮对晚期恶性肿瘤患者生活质量的改善作用[J].中草药，2012，43（7）：1385-1386.
[17] 郑爱红，吴国清，薛骞.注射用黄芪多糖联合静脉热化疗治疗晚期非小细胞肺癌临床疗效观察[J].中华中医药学刊，2012，30（4）：926-928.
[18] Zivkovic V，Jakovljevic V，Djordjevic D，et al. The effects of homocysteine-related compounds on cardiac contrac?鄄tility，cor-onary flow，and oxidative stress markers in isolated rat heart [J]. Mol Cell Biochem，2012，370（1/2）：59-67.
[19] 张守文，张小霞，石增成，等.卡维地洛联合曲美他嗪对接受含蒽环类药物化疗乳腺癌患者的心脏保护作用[J].中国全科医学，2016，19（7）：794-798.
[20] 留佳，梁晓美，曾菁，等.注射用黄芪多糖在胃癌术后化疗中的作用及化疗后毒副反应处理[J].中国现代医生，2015，53（23）：101-103，107.
[21] Adelibieke Y，Yisireyili M，Ng HY，et al. Indoxyl sulfate induces IL-6 expression in vascular endothelial and smooth muscle cells through OAT3-mediated uptake and activa?鄄tion of AhR/NF-κB pathway [J]. Nephron Exp Nephrol，2014，128（1/2）：1-8.